Skip to main content
. 2016 Jan 12;3:153–159. doi: 10.1016/j.toxrep.2016.01.006

Fig. 3.

Fig. 3

Survival of HEK293 cells treated pre- or delayed-cisplatin (50 or 80 μM) with Nrf2 activators [oltipraz (12 μM), sulforaphane (5 μM), oleanolic acid (5 μM)] incubated for 12, 24, or 48 h. (A) HEK293 cells treated pre- cisplatin (80 μM) with Nrf2 activators, (B) HEK293 cells treated with delayed-cisplatin (80 μM) with Nrf2 activators, (C) HEK293 cells treated pre-cisplatin (50 μM) with Nrf2 activators, and (D) HEK293 cells treated with delayed-cisplatin (50 μM) with Nrf2 activators. Data are means ± SEM. (n = 4–6). *p < 0.05 compared to vehicle controls (DMSO), #p < 0.05 compared to 50 μM or 80 μM cisplatin-treated cells.